REFERENCES [1]Siddiqui U Prevalence and predictors of herbal medication use in veterans with chronic hepatitis C. J Clin Gastroenterol. 2004 Aug;38(7):605-10. [2] Wallace SN Extraction of nutraceuticals from milk thistle: part II. Extraction with organic solvents. Appl Biochem Biotechnol. 2003 Spring;105 -108:891-903. [3] Wallace SN Batch solvent extraction of flavanolignans from milk thistle (Silybum marianum L. Gaertner). Phytochem Anal. 2005 Jan-Feb;16(1):7-16. [4]Duan L Silymarin extraction from milk thistle using hot water. Appl Biochem Biotechnol. 2004 Spring;113-116:559-68.[5] Lee DY, Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle). J Nat Prod. 2003 Dec;66(12):1632. [6] Kim NC Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem. 2003 May 21;1(10):1684-9.[7] Manna SK Silymarin [MILK THISTLE] suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999 Dec 15;163(12):6800-9. [8] Lee DG et al Gram-positive bacteria specific properties of silybin derived from Silybum marianum [Milk Thistle]. Arch Pharm Res. 2003 Aug;26(8):597-600.[9] Soliman KF In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by various dietary compounds. Proc Soc Exp Biol Med. 1998 Sep;218(4):390-7.[10] Bialecka M. The effect of bioflavonoids and lecithin on the course of experimental atherosclerosis in rabbits Ann Acad Med Stetin. 1997;43:41-56. [11]Zi X, Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin [MILK THISTLE]: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun. 1997 Oct 9;239(1):334-9.[12]Tyagi A Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 2004 Sep;25(9):1711-20. Epub 2004 Apr *milk thistle [13]Tyagi AK Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochem Biophys Res Commun. 2003 Dec 26;312(4):1178-84.[14] Vinh PQ et al Chemopreventive effects of a flavonoid antioxidant silymarin [MILK THISTLE] on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Jpn J Cancer Res. 2002 Jan;93(1):42-9. [15]Tyagi AK Synergistic anti-cancer effects of silibinin [milk thistle extract] with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004 Feb;11(2):493-9.Zi X. Anticarcinogenic effect of a flavonoid antioxidant, silymarin [milk thistle], in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res. 1998 Apr;4(4):1055-64.[17] Kohno H et al, Silymarin [MILK THISTLE], a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer. 2002 Oct 10;101(5):461-8.[18] Yoo HG Involvement of NF-kappaB and caspases in silibinin-induced apoptosis of endothelial cells. Int J Mol Med. 2004 Jan;13(1):81-6.[19] Qi L, Epidermal growth factor receptor mediates silibinin [milk thistle]-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther. 2003 Sep-Oct;2(5):526-31.[20] Chu SC Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog. 2004 Jul;40(3):143-9.[21] Ladas EJ Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? J Altern Complement Med. 2003 Jun;9(3):411-6.[22] [Davis-Searles PR, Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum [MILK THISTLE] on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 2005 May 15;65(10):4448-57] [23] Singh RP A cancer chemopreventive agent silibinin [MILK THISTLE], targets mitogenic and survival signaling in prostate cancer. Mutat Res. 2004 Nov 2;555(1-2):21-32.[23] Thelen P Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells. Planta Med. 2004 May;70(5):397-400.[24] Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin [milk thistle] in prostate cancer cells. J Urol. 2004 May;171(5):1934-8. [25] Prostate cancer prevention by silibinin [milk thistle]. Curr Cancer Drug Targets. 2004 Feb;4(1):1-11 [26] A flavonoid antioxidant, silymarin [milk thistle], inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res. 1998 May 1;58(9):1920-9. 27 Silibinin [Milk Thistle] decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7490-5. 28 Dhanalakshmi S Silibinin [MILK THISTLE] sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer. 2003 Sep 20;106(5):699-705. 29 Zi X Silibinin [MILK THISTLE] up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells Cancer Res. 2000 Oct 15;60(20):5617-20. [30] Singh RP Dietary feeding of [MILK THISTLE] silibinin inhibits advance human prostate carcinoma growth in athymic mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 2002 Jun 1;62(11):3063-9. [31]Tyagi A et al, Silibinin [MILK THISTLE] strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res. 2002 Nov;8(11):3512-9. [32] Tyagi A Antiproliferative and apoptotic effects of silibinin [MILK THISTLE] in rat prostate cancer cells. Prostate. 2002 Nov 1;53(3):211-7.[33]Katiyar SK et al, Protective effects of silymarin [milk thistle] against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst. 1997 Apr 16;89(8):556-66][34] Katiyar SK. Silymarin [milk thistle] and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review). Int J Oncol. 2005 Jan;26(1):169-76.[35] Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis. 2004 Aug;25(8):1459-65. Epub 2004 Mar 19. [36]A flavonoid antioxidant, silymarin [milk thistle], affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 1999 Feb 1;59(3):622-32[36] Yanaida Y et al Dietary silymarin [MILK THISTLE] suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Carcinogenesis. 2002 May;23(5):787-94.[37]Silymarin [Milk thistle]: potent inhibitor of cyclic AMP phosphodiesterase. Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):409-13.][38]Crocenzi FA et al, Silibinin [Milk thistle] prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte couplets: possible involvement of cAMP. Biochem Pharmacol. 2005 Apr 1;69(7):1113-20.] [39] von Schonfeld J Silibinin [Milk thistle], a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell Mol Life Sci. 1997 Dec;53(11-12):917-20.] [40] Maghrani M Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum [Milk thistle] in an animal model of type 1 diabetes mellitus. J Ethnopharmacol. 2004 Apr;91(2-3):309-16. [41] Chlopcikova S Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin [Milk thistle] and its flavonolignans. Phytother Res. 2004 Feb;18(2):107-10. [42] Katiyar SK. Treatment of silymarin [MILK THISTLE], a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol. 2002 Dec;21(6):1213-22. [43]Wilasrusmee C et al, Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Med Sci Monit. 2002 Nov;8(11):BR439-43.[44] Ferenci P et al, Randomized controlled trial of silymarin [Milk thistle] treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul;9(1):105-13. [45] Arteel G Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):625-47.[46] Lieber CS Silymarin [Milk thistle] retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol. 2003 Oct;37(4):336-9.[47]. Dehmlow C. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996 Apr; 23 (4): 749-54. [48]. Wu DF The effects of silymarin [Milk thistle] on hepatic microsomal and mitochondrial membrane fluidity in mice. Zhongguo Zhong Yao Za Zhi. 2003 Sep;28(9):870-2. [49] Tanamly MD et al, Randomised double-blinded trial evaluating silymarin [Milk thistle] for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004 Nov;36(11):752-9. [50]Tedesco D Silymarin, a possible hepatoprotector in dairy cows: biochemical and histological observations. J Vet Med A Physiol Pathol Clin Med. 2004 Mar;51(2):85-9.[51] Wang MJ Silymarin [MILK THISTLE] protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci. 2002 Dec;16(11):2103-12 [52] Kittur S et al, Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. J Mol Neurosci. 2002 Jun;18(3):265-9. [53] Hu Z, Herb-drug interactions: a literature review. Drugs. 2005;65(9):1239-82.][54]DiCenzo R Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy. 2003 Jul;23(7):866-70.[55] Giese LA. Milk thistle and the treatment of hepatitis. Gastroenterol Nurs. 2001 Mar-Apr;24(2):95-7. [56] Saller R et al, The use of silymarin in the treatment of liver diseases Drugs. 2001;61(14):2035-63.[57] Ferenci P. et al, Randomized controlled trial of silymarin (milk thistle) treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul;9(1):105-13. [58]Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med. 2003 Jan;69(1):44-9.[59] Jacobs BP, Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med. 2002 Oct 15;113(6):506-15.[60] Rambaldi A. et al, Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003620.][61] Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med. 2003 Jan;69(1):44-9. [aa1] Raza SS, t al, Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia: a behavioral, biochemical and immunohistological study in Wistar rats. J Neurol Sci. 2011 Oct 15;309(1-2):45-54. [aa2] Suksomboon N et al, Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol. 2011 Aug 5 [aa3] Kim JL,et al, Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts.J Cell Biochem. 2011 Sep 6 [aa4] Lian R, et al, Silymarin Glyceryl Monooleate/Poloxamer 407 Liquid Crystalline Matrices: Physical Characterization and Enhanced Oral Bioavailability. AAPS PharmSciTech. 2011 Sep 23. |
Milk Thistle Reference October 18, 2011 |